NCT05304533View on ClinicalTrials.gov

A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 21, 2022

Primary Completion Date

November 14, 2022

Study Completion Date

November 29, 2022

Conditions
Healthy Participants
Interventions
DRUG

MYK-224

Specified dose on specified days

DRUG

Itraconazole

Specified dose on specified days

DRUG

Verapamil

Specified dose on specified days

Trial Locations (1)

75247

Local Institution - 0001, Dallas

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05304533 - A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy Participants | Biotech Hunter | Biotech Hunter